Literature DB >> 32202617

Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.

Liang Guo1,2, Chunmei Cao1,2, Shyamal Goswami3, Xiaoyan Huang1,2, Linxiaoxi Ma1,2, Yicheng Guo4, Benlong Yang1,2, Teng Li3, Yayun Chi1,2, Xiaoming Zhang3, Jiong Wu1,2,5.   

Abstract

Tumor-infiltrating PD-1hi dysfunctional CD8+ T cells have been identified in several tumors but largely unexplored in breast cancer (BC). Here we aimed to extensively explore PD-1hiCD8+ T cells in BC, focusing on the triple-negative BC (TNBC) subtype. Flow cytometry was used to study the phenotypes and functions of CD8+ T-cell subsets in peripheral blood and surgical specimens from treatment-naive BC patients. RNA-seq expression data generated to dissect the molecular features of tumoral PD-1neg, PD-1lo and PD-1hi CD8+ T cells. Further, the associations between tumoral PD-1hi CD8+ T cells and the clinicopathological features of 503 BC patients were explored. Finally, multiplexed immunohistochemistry (mIHC) was performed to evaluate in situ PD-1hiCD8+ T cells on the tissue microarrays (TMAs, n=328) for prognostic assessment and stratification of TNBC patients. PD-1hiCD8+ T cells found readily detectable in tumor tissues but rarely in peripheral blood. These cells shared the phenotypic and molecular features with exhausted and tissue-resident memory T cells (TRM) with a skewed TCR repertoire involvement. Interestingly, PD-1hiCD8+ T cells are in the state of exhaustion characterized by higher T-BET and reduced EOMES expression. PD-1hiCD8+ T cells found preferentially enriched within solid tumors, but predominant stromal infiltration of PD-1hiCD8+ T subset was associated with improved survival in TNBC patients. Taken together, tumoral PD-1hiCD8+ T-cell subpopulation in BC is partially exhausted, and their abundance signifies 'hot' immune status with favorable outcomes. Reinvigorating this population may provide further therapeutic opportunities in TNBC patients.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  PD-1; T cell exhaustion; prognosis; triple-negative breast cancer

Year:  2020        PMID: 32202617     DOI: 10.1042/CS20191261

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

Review 1.  Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies.

Authors:  Corinna Keup; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Care (Basel)       Date:  2020-10-07       Impact factor: 2.860

2.  Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.

Authors:  Meghan J O'Melia; Margaret P Manspeaker; Susan N Thomas
Journal:  Cancer Immunol Immunother       Date:  2021-01-18       Impact factor: 6.630

3.  Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers.

Authors:  Zhenyu Yang; Yulan Deng; Jiahan Cheng; Shiyou Wei; Hao Luo; Lunxu Liu
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

4.  A comprehensive profile of TCF1+ progenitor and TCF1- terminally exhausted PD-1+CD8+ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy.

Authors:  Dikan Wang; Juan Fang; Shuqiong Wen; Qunxing Li; Jinming Wang; Lisa Yang; Wenxiao Dai; Huanzi Lu; Junyi Guo; Zhongyan Shan; Wenqiang Xie; Xiangqi Liu; Liling Wen; Jie Shen; Anxun Wang; Qianming Chen; Zhi Wang
Journal:  Int J Oral Sci       Date:  2022-02-14       Impact factor: 6.344

5.  Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.

Authors:  Yves Boucher; Ashwin S Kumar; Jessica M Posada; Evisa Gjini; Kathleen Pfaff; Mikel Lipschitz; Ana Lako; Dan G Duda; Scott J Rodig; F Stephen Hodi; Rakesh K Jain
Journal:  NPJ Precis Oncol       Date:  2021-06-29

6.  Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.

Authors:  Han-Ning Li; Xing-Rui Li; Zheng-Tao Lv; Miao-Miao Cai; Ge Wang; Zhi-Fang Yang
Journal:  Cancer Med       Date:  2020-10-14       Impact factor: 4.452

Review 7.  Prospects of Immunotherapy for Triple-Negative Breast Cancer.

Authors:  Dan Qiu; Guijuan Zhang; Xianxin Yan; Xinqin Xiao; Xinyi Ma; Shujun Lin; Jieyan Wu; Xinyuan Li; Wandi Wang; Junchen Liu; Yi Ma; Min Ma
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

8.  Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.

Authors:  Yujun Park; An Na Seo; Jiwon Koh; Soo Kyoung Nam; Yoonjin Kwak; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim; Hye Seung Lee
Journal:  Oncoimmunology       Date:  2021-07-25       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.